Sorry, you can't just say these things without evidence. You look foolish. That said, I hope it's true...
Brent said that "The current climate of uncertainty in the financial markets has created opportunities for well-capitalized companies that were simply not available even a few months ago"
My interpretation of this is that he's looking for a sale. Thoughts?
Wow - that's some earthquake. Are you saying Bostonians will wake up and see the Ipanema beach out of their window soon? The statue of Christ the Redeemer? They're in for a treat.
But seriously, some real idiots have suddenly appeared on here. I take their panicky nonsensical gibberish as a good sign.
Eminent dilution? Perhaps you could explain this concept? Do you mean it's very important, noble, of great standing? I'm dying to find out.
Meanwhile, thanks for the laugh. Your presidency was equally laughable.
Great recognition from Forbes:
"Inovio has previously seen success with DNA-based vaccines for other mosquito-transmitted viruses like West Nile, dengue and chikungunya. Having recently received $45 million in funding from the U.S. Defense Advanced Research Projects Agency (DARPA) for Ebola research, the company hopes to attract similar support for a Zika vaccine so it can develop an effective product as quickly as possible. Pharmaceutical giants Glaxo and Sanofi also hope to produce a Zika vaccine and are currently conducting feasibility studies to determine if their existing technologies can be used to create treatments. As a result, the two companies are trailing behind Inovio in terms of both vaccine progress and stock market gains."
Sentiment: Strong Buy
Per Clint Carlson’s Carlson Capital L P’s filing, the filler now owns 7.37% of the company, holding 12,414,223 shares.
Cosan Limited(USA) (NYSE:CZZ) is a newly disclosed equity position for the hedge fund and the filing was required due to activity on December 31, 2015. This most probably shows Clint Carlson’s Carlson Capital L P’s confidence and optimism in the future of the company. As a hedge fund with $20.59 billion AUM and 168+ professional employees, we have no reason to doubt they didn’t do their homework before buying such a stake.
Sorry, market. Accidentally gave you a thumbs down. You're right - dcaf is one of the very few worthwhile posters here. Thanks, both.
Thanks for that fantastically informative post. Really, thanks. Your advice is invaluable.
'Director Warren Whitehead purchased 50,000 shares of Telesta Therapeutics stock in a transaction on Monday, December 7th.'
Seems some people still have confidence in the company. I'm going to wait this out.
No denying that the No vote was decisive, but frequently with positive commentary on its prospects,” says the analyst. “We are quite prepared to take our lumps on negative clinical and/or regulatory events for technology developers in our coverage universe (and we have!), but to be blunt, some of the criticisms of MCNA by the No voters were just baffling to us, and with impractical consequences. First of all, the post-vote explanations from the No voters were frequently quite positive on MCNA’s medical utility (huh?), and there was clearly no guidance from Panel administrators on the incongruity of these two lines of thought. We heard the phrase that MCNA ‘sure would be nice to have’ more than once during the day. Secondly, more than one panelist effectively criticized MCNA for having a benign safety profile (again, huh?), citing this as a reason why MCNA could discourage other new therapies from being tested in BCG-refractory disease, maybe on the concern that future drugs would be compared more to MCNA’s safety than to its efficacy. We have just never heard of this as a concern for any developmental therapy we have reviewed.”
In a research update to clients today, Loe downgraded Telesta Therapeutics from “Speculative Buy” to “Hold” and cut his one-year price target from $1.70 to $0.30, implying a return of 24.1 per cent at the time of publication.